To further validate this possibility, we analyzed the levels of TLR2 in the brains of PD/DLB patients (Fig. 1a-c) and in a transgenic mouse model expressing high levels (3–4 fold) of human α-synuclein under the mThy1 promoter (α-Syn-tg; Line 61) using immunolabeling analysis (Fig. 1d-f) [23]. The gene discussed is TG; the disease is Parkinson disease.